El interés en corto de AEON Biopharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de AEON Biopharma. Los datos de interés en corto se actualizan cada dos semanas.

AEON Biopharma (AMEX:AEON) Bolsa, Informe de interés en corto

AEON Biopharma

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma Inc

AEON CREDIT SERVICE ASIA by Aeon Credit Service Asia Company Ltd

AEON Co Ltd

AEON DELIGHT CO LTD by Aeon Delight Co., Ltd.

AEON DELIGHT Co Ltd

AEON FANTASY CO LTD by AEON Fantasy Co., Ltd.

AEON FINCL SVCS JPN ORD by Aeon Financial Services Co., Ltd.

AEON Financial Service Co Ltd

AEON Mall Co Ltd

AEON REIT INVT CORP by AEON REIT INVT CORP.

AEON REIT Investment Corp

Aeon Credit Service (Asia) Co Ltd

OPTN

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

COEPW

COEP

CARA

The private space industry had a breakout year in 2024 and the upward trend looks poised to continue into 2025. Here's a look at the trends that could shape the future of <a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024">the space industry.&nbsp;</a>
Trump Catalyst: Investors are gearing up for incoming President Donald Trump who oversaw the establishment of NASA's Artemis program, the re-launch of the National Space Council and the creation of the Space Force during his first term in office.&nbsp;
James Bruegger, chief investment officer of Seraphim Space, also sees space being a focus of the second Trump administration, especially in the face of China's "increasing assertiveness" in space technology. 
Read Next: <a href="https://www.benzinga.com/general/social-media/24/12/42734220/bill-ackman-sends-fannie-mae-freddie-mac-stocks-soaring-trump-likes-big-deals">Bill Ackman Sends Fannie Mae, Freddie Mac Stocks Soaring: &#8216;Trump Likes Big Deals&#8217;</a>&nbsp;
Communication Satellites: Bruegger also said he expects 2025 to be the year that direct-to-device satellite connectivity goes mainstream and pointed to Apple's recent $1.5 billion investment in Globalstar as an example.&nbsp;
AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices and could benefit from other carriers looking to space to improve connectivity. The company recently announced <a href="https://www.benzinga.com/24/12/42390726/ast-spacemobile-secures-long-term-vodafone-deal-to-boost-global-coverage">a partnership</a> with Vodaphone to expand the carrier's global broadband connectivity. 
Market Interest: Investors showed growing interest in private space companies in 2024 and Bruegger expects the trend to continue into 2025. He pointed to Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) as one of the most valuable private space companies with a market cap of $13.61 billion as of Monday. Rocket Lab shares have gained more than 375% in 2024. 
Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is another space company to watch in the new year. The company successfully landed its Odysseus lunar lander on the moon in February 2024 to become the first U.S. spacecraft to land on the surface of the moon since the end of the Apollo era in the 1970s. 
The company is positioned for continued growth in 2025 with long-term NASA contracts and two new contract awards from NASA's Near Space Network <a href="https://www.benzinga.com/general/sports/24/12/42647377/intuitive-machines-stock-is-moving-higher-monday-whats-going-on">announced</a> last week. Intuitive Machines shares are up over 640% this year.&nbsp;
"As we look ahead to 2025, we expect it to be once again a stellar year for SpaceTech," Bruegger said.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42687945/zelle-became-a-gold-mine-for-fraudsters-consumer-financial-protection-bureau-lawsuit">&nbsp;&#8216;Zelle Became A Gold Mine For Fraudsters&#8217;: Consumer Financial Protection Bureau Lawsuit</a></li>
</ul>
Photo: Shutterstock

News

SPACE

Movers

Tech

General

ASTS

LUNR

RKLB

Space Industry To See Another 'Stellar Year' In 2025, Investor Says

Legendary investor Warren Buffett is best known for stocks he has bought over the years and his gains for Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) investors. He's also <a href="https://www.benzinga.com/general/education/24/10/41418702/warren-buffetts-words-of-wisdom-benzinga-readers-pick-their-favorite-oracle-of-omaha-quote">known for quotes</a> that can be applied to investing and life.
Here's a look back at Buffett's take on the importance of reputation.
What Happened: Buffett has many highlights during his lengthy career leading Berkshire Hathaway, but one of the lower moments almost occurred<a href="https://www.benzinga.com/news/16/09/8483241/warren-buffett-weathered-the-salomon-brothers-scandal-whats-that-mean-for-wells-f"> due to an investment </a>in investment bank Salomon Brothers.
Berkshire bought a 12% stake in the company in the 1980s and a scandal at the firm over treasury bonds almost took the company under and led to Buffett stepping in as interim chairman and CEO of the company.
In September 1991, Buffett <a href="https://www.youtube.com/watch?v=7u7-UNSkr4o">testified </a>before the House Commerce subcommittee in Washington D.C. and shared that he asked every Salomon Brothers employee to be their own compliance officer.
He also asked for two key demands from employees with the first one being that they obey all rules and ask themselves if they're willing to appear on the front page of the newspaper and have their work accomplishments read by their spouses and kids.
If they followed this rule, Buffett was pretty confident they could ignore his second demand.
"Lose money for the firm and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless," Buffett said in the hearing.
Salomon Brothers was later <a href="https://archive.nytimes.com/dealbook.nytimes.com/2008/09/24/warren-buffett-and-the-salomon-saga/">acquired </a>by Travelers Group, netting a profit for Berkshire Hathaway and showing how Buffett helped saved the company. 
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Buffett has used the Salomon Brothers case as an important learning lesson over the years when discussing the newspaper test and the value of reputation.
Salomon Brothers knew one of their employees was a bad actor and didn't report and kept trying to shove the story away, before coming within inches of destroying the company, Buffett once said.
Buffett said all the company had to do was pick up the phone and report the trading activity but instead former Salomon CEO John Gutfreund, who was once called the "King of Wall Street," destroyed his career.
One of Buffett's most important lessons he tells his managers revolves around the concept of reputation.
"We can afford to lose money, even a lot of money. We can't afford to lose reputation. Even a shred of reputation. Let's be sure that everything we do in business can be reported on the front page of a national newspaper," Buffett <a href="https://www.youtube.com/watch?v=C5_vvcnFCgM">said </a>in another interview.
In the interview, Buffett mentioned that Berkshire Hathaway had been named one of the most admired companies in the world, something that took 37 years to accomplish.
"We could lose it in 37 minutes and that's the message."
Buffett said that once reputation is lost, you may not get it back.
"Can lose it in five minutes."
A strong focus on reputation could be among the reasons why Berkshire Hathaway has stood the test of time and Buffett has been able to spot good CEOs and companies to invest in.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/12/42706002/warren-buffett-said-selling-disney-was-a-huge-mistake-legendary-investor-should-have-been-buying">Warren Buffett Said Selling Disney &#8216;Was A Huge Mistake&#8217;: Legendary Investor &#8216;Should Have Been Buying&#8217;</a></li>
</ul>
Photo: Shutterstock

Education

Management

Success Stories

Warren Buffett's Chilling Warning To Employees: 'Lose A Shred Of Reputation For The Firm And I Will Be Ruthless'

Kevin O'Leary, chairman of O'Leary Ventures and a prominent investor on Shark Tank, was straightforward during a recent <a href="https://www.youtube.com/watch?v=4pS2TdlwT7Q">interview</a> on Fox Business. He firmly declared that it was time to stop treating China as a developing nation, calling the status outdated and unfair. O'Leary also warned that China is engaged in what he described as &#8220;an economic war with us.&#8221;
The investor pointed out a significant issue with how the World Trade Organization (WTO) designates China as a developing nation. This classification allows China to receive special benefits, including sweetheart loans that O'Leary says American taxpayers partially fund. He stated bluntly, "China is not a developing nation. They're at economic war with us and European countries."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
O'Leary explained that these benefits have <a href="https://www.benzinga.com/startups/24/08/40544141/they-have-screwed-me-over-the-last-12-years-says-kevin-oleary-cheers-for-tariffs-squeeze-chinese-hea">given China an unfair advantage</a> for decades. "Forty years of getting screwed, that's what happened," he said, highlighting how the U.S. and other nations have essentially subsidized China's rise while their economies have faced challenges.
<h2 class="wp-block-heading">A Hardline Stance on Trade</h2>
O'Leary shared his frustrations as a business owner who has faced what he described as unfair practices by China. "They don't play by the rules; there's nothing reciprocal in our relations," he said. For O'Leary, the solution is clear: hit China where it hurts most – their economy. He argued that the only way to get China's attention is through "very selected <a href="https://www.benzinga.com/news/24/10/41417400/kevin-oleary-calls-for-400-tariffs-on-china-but-his-shark-tank-co-star-and-billionaire-investor-mark">high-impact weaponry like tariffs</a>."
According to O'Leary, imposing tariffs on sectors critical to Chinese employment could force the government to rethink its approach. "If you want to mess with the largest economy that you trade with, we will force a lot of people that make yoga mats or electronics or whatever else it is to be unemployed in your city," he said. "They'll be rioting in the streets, and you'll be out of power."
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">Time to Get Tough</h2>
O'Leary expressed hope that the future administration would address the problem head-on. He underscored the importance of a hard-line approach, saying, "You gotta be hard core. [President Xi] only understands the stick. That's all he understands."
O'Leary's comments reflected his belief that the U.S. has been too lenient with China for far too long. He blamed previous administrations – Democratic and Republican – for continuing this scenario. "When there's a Democrat in the White House, they go right along," he said, pointing to a history of inaction.
Read Next:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

'China Is Not A Developing Nation,' Says Kevin O'Leary Claims They're At 'An Economic War With Us'

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 20 years by 1.44% on an annualized basis producing an average annual return of 9.77%. Currently, Travelers Companies has a market capitalization of $54.46 billion. 
Buying $100 In TRV: If an investor had bought $100 of TRV stock 20 years ago, it would be worth $648.65 today based on a price of $239.87 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735600507_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Travelers Companies Stock In The Last 20 Years

The U.S. Treasury Department announced on Monday it was targeted by a Chinese state-sponsored hacking group that gained unauthorized access to government workstations and unclassified documents. This revelation, detailed in a letter reviewed <a href="https://www.washingtonpost.com/technology/2024/12/30/treasury-hack-china-national-security/">by</a>&nbsp;The Washington Post, highlights significant vulnerabilities in federal cybersecurity infrastructure.
The breach was discovered on Dec. 8, when BeyondTrust, a third-party software provider, notified the department that a hacker had exploited a security key. This key enabled the intruder to bypass critical security protocols and infiltrate Treasury Department office workstations, gaining access to sensitive but unclassified documents stored on them. The Treasury Department subsequently classified the incident as a &#8220;major incident,&#8221; aligning with its policy of treating nation-state cyber intrusions as significant threats.
Treasury officials are working with law enforcement and the Cybersecurity and Infrastructure Security Agency (CISA), a Treasury spokesperson said in a <a href="https://www.cnn.com/2024/12/30/investing/china-hackers-treasury-workstations/index.html">statement to</a> CNN, and that the compromised service has been taken offline.
"There is no evidence indicating the threat actor has continued access to Treasury systems or information," the Treasury spokesperson said, per CNN.
See Also: <a href="https://www.benzinga.com/news/global/24/12/42643821/biden-administration-initiates-trade-probe-on-chinese-legacy-chips">Biden Administration Initiates Trade Probe On Chinese &#8216;Legacy&#8217; Chips</a>
The hack underscores escalating cyber threats from foreign actors, particularly China, which has been implicated in several high-profile cyber intrusions targeting U.S. government and private sector systems. 
The breach also raises questions about the reliance on third-party software providers for critical operations and the adequacy of existing security protocols. Experts warn that such intrusions could potentially compromise sensitive government data and disrupt essential services, underscoring the need for robust cybersecurity strategies and increased investments in digital defense mechanisms.
This article was generated using artificial intelligence.
Read Next: <a href="https://www.benzinga.com/general/social-media/24/12/42730341/gamestops-comeback-trumps-meme-stock-magic-retail-vs-wall-street-2024">• GameStop&#8217;s Comeback, Trump&#8217;s Meme Stock Magic: Retail Vs. Wall Street 2024</a>
Photo: Shutterstock

Government

Legal

Global

China-Linked Hackers Breach US Department Of Treasury

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 1.96% on an annualized basis producing an average annual return of 13.54%. Currently, Analog Devices has a market capitalization of $105.37 billion. 
Buying $1000 In ADI: If an investor had bought $1000 of ADI stock 15 years ago, it would be worth $6,711.71 today based on a price of $212.31 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735599607_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) has outperformed the market over the past 5 years by 5.8% on an annualized basis producing an average annual return of 18.58%. Currently, CRH has a market capitalization of $62.67 billion. 
Buying $100 In CRH: If an investor had bought $100 of CRH stock 5 years ago, it would be worth $225.51 today based on a price of $92.46 for CRH at the time of writing.
<h3>CRH's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735598714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 27.29% on an annualized basis producing an average annual return of 38.69%. Currently, Comfort Systems USA has a market capitalization of $15.20 billion. 
Buying $1000 In FIX: If an investor had bought $1000 of FIX stock 10 years ago, it would be worth $25,860.84 today based on a price of $427.00 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735597818_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Comfort Systems USA 10 Years Ago Would Be Worth Today

&nbsp;S&amp;P MidCap 400 constituent SouthState Corp. is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

ACAD

IBTX

Acadia Pharmaceuticals To Replace Independent Bank Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On January 3, 2025

NYSE Regulation reached its decision to delist the Company's Class A common stock pursuant to Section 802.01B of the NYSE's Listed Company Manual.
 &nbsp;

DNMR

NYSE To Begin Delisting Proceedings Against Danimer Scientific

Fannie Mae (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTC">FNMA</a>) and Freddie Mac (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FMCC#OTC">FMCC</a>) shares soared on Monday afternoon after billionaire investor Bill Ackman touted the<a href="https://www.benzinga.com/markets/24/12/42635629/bill-ackmans-advice-stay-away-from-shorting-stocks-avoid-commodity-sensitive-industries-and-you-do-great"> stocks on social media. </a>
The Details: Ackman, CEO of Pershing Square hedge fund, recommended the stocks as an investment with "large asymmetric upside versus downside" in <a href="https://x.com/BillAckman/status/1873818034428694837">a post</a> on the social media platform X.&nbsp;
Ackman said he sees the potential for Fannie Mae and Freddie Mac to come out of conservatorship in the next two years. Ackman pointed to the incoming Trump administration as a factor making the end of conservatorship more likely for the home lenders. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am often asked for stock recommendations, but generally don't share individual names unless I believe the risk versus the reward is extraordinarily compelling. As we look toward 2025, one investment in our portfolio stands out for large asymmetric upside versus downside so I…
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1873818034428694837?ref_src=twsrc%5Etfw">December 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Fannie Mae and Freddie Mac were placed under conservatorship in September 2008 in response to the deterioration of the housing market during the 2008 financial crisis. The Federal Housing Finance Agency became the conservator to preserve and conserve the assets and to provide stability to the housing and mortgage markets.&nbsp;
Read Next: <a href="https://www.benzinga.com/24/12/42700819/investors-bet-on-milei-the-argentina-trade">Milei&#8217;s Economic Chainsaw Slashes Inflation As Argentine Stocks Explode 175%</a>&nbsp;
Ackman said that the companies have built $168 billion of capital since 2019 and described this as a "fortress-level of capital for guarantors of fixed-rate, first mortgages to creditworthy, middle class borrowers."&nbsp;
Ackman said he estimates the value of each company at approximately $34 per share, assuming the companies could IPO in the fourth quarter of 2026. He added that he sees the IPOs priced at approximately $31 per share accounting for a 10% discount to their value.&nbsp;&nbsp;
He also pointed to the benefits of ending the conservatorship for the federal government including the removal of approximately $8 trillion in liabilities and the potential to generate more than $300 billion in profits. 
"Trump likes big deals and this would be the biggest deal in history. I am confident he will get it done," Ackman wrote.&nbsp;
FNMA, FMCC Price Action: Fannie Mae shares ended Monday&#8217;s session up 36.14% at $3.39 and Freddie Mac shares closed 33.87% higher at $3.32.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42687945/zelle-became-a-gold-mine-for-fraudsters-consumer-financial-protection-bureau-lawsuit">&nbsp;&#8216;Zelle Became A Gold Mine For Fraudsters&#8217;: Consumer Financial Protection Bureau Lawsuit</a></li>
</ul>
Photo: Shutterstock

Social Media

FMCC

FNMA

Bill Ackman Sends Fannie Mae, Freddie Mac Stocks Soaring: 'Trump Likes Big Deals'

CORT

Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 4.82% on an annualized basis producing an average annual return of 16.23%. Currently, Cencora has a market capitalization of $43.43 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 10 years ago, it would be worth $447.90 today based on a price of $224.71 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735596907_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

Ms. Chen's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operation, policies or practices.

Warner Bros. Discovery Says Li Haslett Chen Notified Her Decision To Resign From Board, Effective As Of January 31, 2025

President Jimmy Carter, who <a href="https://www.benzinga.com/movers-shakers/24/12/42716329/jimmy-carter-the-39th-us-president-who-championed-human-rights-and-peace-in-the-middle-east-had-died">died at his home</a> on Sunday at age 100, brought a political outsider status to Washington, D.C. during a period of immense distrust in government. 
There was the Watergate scandal, high inflation, mass protests due to the Vietnam War, high government spending and loose monetary policy. 
Carter, a Georgian native who won the White House in 1976, inherited an economy reeling from a recession and subsequent inflation proved disastrous for his 1980 reelection bid.
<a href="https://fred.stlouisfed.org/series/FPCPITOTLZGUSA">According</a> to the Federal Reserve Bank of St. Louis, inflation neared 6% in 1976 before Carter&#8217;s presidency began. 
Carter then presided over 6.5%, 7.5%, 11.3% and 13.5% inflation in successive years. Economists consider 2% to be a healthy rate of inflation.
&#8220;In the last 10 years, in our attempts to protect ourselves from inflation, we've developed attitudes and habits that actually keep inflation going once it has begun,&#8221; the 39th U.S. President <a href="https://www.bls.gov/opub/mlr/2014/article/one-hundred-years-of-price-change-the-consumer-price-index-and-the-american-inflation-experience.htm#_edn47">said</a> in 1978.
&#8220;Most companies raise their prices because they expect costs to rise. Unions call for large wage settlements because they expect it to happen, and once it's started, wages and prices chase each other up and up. It's like a crowd standing at a football stadium. No one can see any better than when everyone is sitting down, but no one is willing to be the first to sit down.&#8221;
In 1979, Carter nominated Paul Volcker, then the president of the Federal Reserve Bank of New York, to chair the Federal Reserve. Volcker <a href="https://www.benzinga.com/government/regulations/22/10/29239702/the-fed-is-skating-to-where-the-puck-was-analogies-to-volckers-1980s-inflation-are-conce-1">hawkishly shaped monetary policy</a> by <a href="https://fred.stlouisfed.org/series/FEDFUNDS">hiking</a> the federal funds rate from 10% to nearly 18%. 
The economy then entered a recession as the unemployment rate neared 8%.
That year, Carter was also dealing with the Iranian Revolution. From April 1979 to November 1980, the price of oil spiked over 130%, <a href="https://www.eia.gov/dnav/pet/hist/LeafHandler.ashx?n=pet&amp;s=f000000__3&amp;f=m">per</a> the Energy Information Administration. This worsened inflation and created &#8220;stagflation,&#8221; an increase in prices and unemployment due to a negative supply shock.
Carter faced a primary challenge from Massachusetts Sen. Ted Kennedy, which he won decisively. But he fared much worse in the general election, suffering a landslide loss to then-California Governor Ronald Reagan. Reagan, a Republican, carried 44 states and won the popular vote by nearly 10%.
Volcker&#8217;s monetary policy and the induced recession did not lend Carter any electoral help. Volcker&#8217;s rate hikes continued during the Reagan administration. They went as high as 21% leading to a prolonged recession in 1981 and 1982. 
Still, economists <a href="https://www.bu.edu/econ/files/2011/01/GKcr2005.pdf">credit</a> Volcker for the historic disinflation and end of high inflation expectations. Inflation remained below 6%, usually hovering around 2%, for several decades following the 1980s.
Historians have increasingly reevaluated Carter&#8217;s presidency. Today, they acknowledge the long-term significance of his decisions despite his administration&#8217;s unpopularity. 
Carter&#8217;s appointing of Volcker as Fed chair was politically costly but is considered a crucial step in curbing historic inflation.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42725647/markets-will-close-for-president-jimmy-carters-state-funeral-what-you-need-to-know">Markets Will Close For President Jimmy Carter&#8217;s State Funeral: What You Need To Know</a></li>
</ul>

Politics

Economics

Federal Reserve

Jimmy Carter's Complex Economic Legacy: High Inflation, But Effective, Hawkish Fed Under Volcker

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on AEON Biopharma (AEON – Research Report), retaining the price target of $6.00. Do...

Buy Rating Affirmed for AEON Biopharma on Strategic Biosimilar Pathway and Promising Phase 3 Study Prospects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!



Moving stocks are new agreements, a patent, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SILO Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock is rocketing more than 69% after <a href="https://www.nasdaq.com/press-release/silo-pharma-secures-exclusive-global-license-alzheimers-therapeutic-2024-07-16">securing a new license</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) shares are soaring over 65% with heavy pre-market trading.</li>



<li>SciSparc (NASDAQ:<a href="https://investorplace.com/stock-quotes/sprc-stock-quote/">SPRC</a>) stock is surging more than 39% on a <a href="https://www.nasdaq.com/press-release/scisparc-announces-us-patent-application-treating-metabolic-syndrome-and-weight-loss">new weight loss patent</a>.</li>



<li>Meiwu Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/wnw-stock-quote/">WNW</a>) shares are rising over 30% with strong early morning trading.</li>



<li>Singing Machine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mics-stock-quote/">MICS</a>) stock is increasing more than 25% on a <a href="https://www.nasdaq.com/press-release/singing-machines-subsidiary-semicab-announces-over-9-million-contracted-revenue">$9 million revenue backlog contract</a>.</li>



<li>Passage Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pasg-stock-quote/">PASG</a>) shares are gaining over 18% on <a href="https://www.nasdaq.com/press-release/passage-bio-announces-positive-feedback-fda-expansion-uplift-d-trial-pbft02-include">clinical trial expansion feedback</a>.</li>



<li>AEON Biopharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aeon-stock-quote/">AEON</a>) stock is climbing more than 16% with strong pre-market trading.</li>



<li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) shares are getting an over 12% boost after <a href="https://www.stocktitan.net/news/SISI/shineco-announces-closing-of-2-million-underwritten-public-r9iot7ulzqfp.html">closing a public offering</a>.</li>



<li>SMX (Security Matters) (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/">SMX</a>) stock is jumping more than 11% <a href="https://www.nasdaq.com/press-release/smx-announces-effective-date-reverse-stock-split-2024-07-11">following a reverse stock split</a>.</li>



<li>Biomerica (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmra-stock-quote/">BMRA</a>) shares are up over 11% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Autonomix Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock is diving more than 18% <a href="https://www.nasdaq.com/press-release/autonomix-enters-definitive-agreement-license-intellectual-property-fda-cleared">following a rally yesterday</a>.</li>



<li>Vince (NYSE:<a href="https://investorplace.com/stock-quotes/vnce-stock-quote/">VNCE</a>) shares are tumbling over 17% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is taking a more than 17% beating on Tuesday morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are sliding over 17% after <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">rising yesterday on a strategic alliance</a>.</li>



<li>Lottery.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltry-stock-quote/">LTRY</a>) stock is dropping more than 16% on Tuesday.</li>



<li>Vicinity Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) shares are decreasing over 16% this morning.</li>



<li>Tantech (NASDAQ:<a href="https://investorplace.com/stock-quotes/tanh-stock-quote/">TANH</a>) stock is falling more than 15% despite a lack of news this morning.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are slipping over 14% on Tuesday morning.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is dropping close to 14% <a href="https://www.benzinga.com/news/24/07/39781479/cyngn-shares-were-up-by-more-than-50-whats-going-on">after a recent rally</a>.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Silo Pharma, Aeon Biopharma, and NaaS Technology are the 3 Penny Stocks to watch on July 18, based on&nbsp;TipRanks' Penny Stock Screener tool. Pen...

3 Penny Stocks to Watch Now, 7/18/24

The latest announcement is out from AEON Biopharma (AEON). AEON Biopharma, Inc. recently updated its investor relations page with a new corporate p...

AEON Biopharma Releases New Corporate Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AEON Biopharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aeon-stock-quote/">AEON</a>) just reported results for the second quarter of 2024.<ul><li>AEON Biopharma reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/aeon-stock-earnings-aeon-biopharma-for-q2-of-2024/">AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024

AEON Biopharma reports Q2 results

AEON receives positive outcome in FDA biosimilar advisory meeting

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on AEON Biopharma (AEON – Research Report) and keeping the price target at $5.00....

Buy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue Projections

AEON Biopharma ( ($AEON) ) has issued an update. AEON Biopharma, Inc. has recently updated its investor community by releasing a new corporate pres...

Comments

AEON Biopharma

Interés en corto

AEON Biopharma (AMEX:AEON) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL